NEW YORK – Tempus AI announced on Friday that it has acquired digital pathology firm Paige for $81.3 million.
纽约——Tempus AI于周五宣布，已以8130万美元收购数字病理学公司Paige。
Tempus is paying for the acquisition primarily through issuance of its common stock, as well as through the assumption of Paige's remaining commitment under its existing Microsoft Azure
Tempus主要通过发行其普通股以及承担Paige在现有Microsoft Azure协议下的剩余承诺来为此次收购提供资金。
cloud services agreement.
云服务协议。
The acquisition will allow Tempus to grow its dataset, expand its technical team, and establish a 'strong footprint' in digital pathology, the company said in a statement.
公司表示，此次收购将使Tempus扩大其数据集，扩充其技术团队，并在数字病理学领域建立“强大的影响力”。
Paige has a dataset that includes nearly 7 million digitized pathology slide images and associated clinical and molecular data. The firm currently offers its US Food and Drug Administration-authorized
Paige拥有一个包含近700万张数字化病理切片图像以及相关临床和分子数据的数据集。该公司目前提供其获得美国食品药品监督管理局授权的
Paige Prostate test
Paige 前列腺测试
to help diagnose prostate cancer, along with multiple research-use-only cancer detection and differentiation solutions.
有助于诊断前列腺癌，同时提供多种仅供研究使用的癌症检测和鉴别解决方案。
'As we embark upon building the largest foundation model that's ever been built in oncology, the acquisition of Paige substantially accelerates our efforts,' Tempus Founder and CEO Eric Lefkofsky said in a statement. 'Paige is a leader in digital pathology and has amassed one of the most comprehensive digital pathology datasets in the world through .
“当我们着手构建迄今为止在肿瘤学领域最大的基础模型时，对Paige的收购大大加速了我们的进程，”Tempus创始人兼首席执行官Eric Lefkofsky在一份声明中表示。“Paige是数字病理学领域的领导者，并通过其积累了世界上最全面的数字病理数据集之一。
its
它的
relationship
关系
with Memorial Sloan Kettering Cancer Center
与纪念斯隆凯特琳癌症中心
. We believe both the Paige team, with their deep generative AI experience, and the dataset they have built, will be catalytic across all of our AI efforts.'
我们相信，拥有深厚生成式人工智能经验的Paige团队及其构建的数据集将对我们在人工智能领域的所有努力起到催化作用。
精彩评论